We investigate the activation status of RTK pathways in GBM tumor biopsies and GBM cell lines and subsequently elaborate the molecular mechanism of resistance to the DNA-alkylating anti-cancer drugs cisplatin and TMZ in three PTEN mutated GBM cell lines and primary GBM cells derived from tumor biopsies. This evidence concerns the gene PTEN and neoplasm.